Validation of the Revised Pretransplant Assessment of Mortality Score in Patients with Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Counseling of patients with acute myelogenous leukemia (AML) for allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a complex task. This is due to the need to balance the potential curative outcome of allo-HSCT with the accompanying high risk of transplantation-associated morbidity and mortality. Thus, assessing a patient's risk profile is critical for effective counseling. Several scoring systems have been developed to predict outcomes after allo-HSCT. One of the most frequently used tools is the Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) [1], which incorporates information on specific comorbidities with weighted scores without including age or disease status.

Source: Biology of Blood and Marrow Transplantation - May 21, 2018 Category: Hematology Authors: Jan M. Middeke, Frederike Kollinger, Henning Baldauf, Friedrich St ölzel, Martin Wermke, Malte von Bonin, Katja Sockel, Cornelia S. Link, Raphael Teipel, Christoph Röllig, Christian Thiede, Uwe Platzbecker, Gerhard Ehninger, Martin Bornhäuser, Johannes Source Type: research